Treatment, outcomes poorer in AML with chromosome abnormality
Chromoanagenesis — an abnormal rearrangement of DNA within the chromosomes of certain cells, including blood cells — links with limited treatment response and poorer outcomes…
Steve Bryson, PhD, science writer — 
Articles by Steve Bryson
Use of dexamethasone may manage Tecvayli’s immune side effect: Study
The use of dexamethasone alone may successfully treat the immune side effect cytokine release syndrome (CRS) in people with relapsed or refractory multiple…
Olverembatinib named ALL breakthrough therapy in China
China has granted breakthrough therapy designation to olverembatinib to be used with low-intensity chemotherapy as a first-line treatment for newly diagnosed people with Philadelphia chromosome-positive…
SIL204 reduces tumors, slows spread in pancreatic cancer models
Administering Silexion Therapeutics‘ investigational therapy SIL204 under the skin effectively reduced the growth of primary tumors and their metastatic spread to various organs in…
Low muscle mass linked to worse outcomes with chemoradiotherapy
Low muscle mass in people with inoperable pancreatic cancer undergoing chemoradiotherapy, or CRT, was linked with more treatment-related toxicities and shorter overall survival in…
Findings can differ in 2 genetic tests guiding ovarian cancer treatment
Discrepancies were identified between two genetic analysis platforms used to detect mutations that guide the treatment of ovarian, fallopian tube, or primary peritoneal cancers in…
Medicaid expansion can raise demand for gynecologic cancer care
An expansion of Medicaid services in the state of Virginia led within months to more young and middle-aged women of lower income being treated in…
New atlas details immune cell changes as disease progresses
Researchers in Belgium have developed an atlas to mark changes in distinct types of immune cells during multiple myeloma’s  progression. Their work, in…
FDA approves Imkeldi, imatinib as oral liquid, for certain leukemias
The U.S. Food and Drug Administration (FDA) has approved an oral liquid formulation of imatinib, now called Imkeldi, to treat specific forms of…
FDA approves revumenib for select acute leukemias with KMT2A defect
The U.S. Food and Drug Administration (FDA) has approved revumenib, now called Revuforj, as an oral therapy for children and adults, ages 1 year and…
